12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

CytRx preclinical data

In animal xenograft models of human GBM, aldoxorubicin significantly reduced tumor growth and more than doubled the mean survival time vs. both doxorubicin and placebo (p<0.0001). CytRx also said that uptake of the compound was confined only to the tumor...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >